Tirzepatide acts as a multi-organ integrator, improving metabolic dysfunction across eight key body systems.

Metabolic diseases like type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) represent a complex, interconnected syndrome. These conditions are characterized by insulin resistance, chronic inflammation, and energy homeostasis disturbances, often affecting multiple organs simultaneously. Current treatments frequently target individual symptoms, leaving a gap for comprehensive therapies that address the systemic nature of these disorders. Tirzepatide, a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, offers a novel approach by targeting multiple metabolic pathways across various organ systems.

This narrative review comprehensively examined the multi-organ effects of tirzepatide, a dual GIP and GLP-1 receptor agonist. Researchers synthesized peer-reviewed sources, including clinical trials (e.g., SURPASS, SURMOUNT programs), preclinical studies, and specialist reviews. The focus was on tirzepatide's physiological impacts across eight key systems: pancreatic β-cells, adipose tissue, liver, gastrointestinal tract, cardiovascular system, kidneys, brain, and gut microbiota. The objective was to detail how tirzepatide integrates therapeutic effects beyond glucose regulation.

Tirzepatide, as a dual GIP and GLP-1 receptor agonist, significantly impacts metabolic regulation. It increases insulin levels and decreases glucagon levels, contributing to improved glycemic control. The peptide slows gastric emptying and promotes feelings of fullness, leading to significant weight loss, as demonstrated in clinical trial programs like SURPASS and SURMOUNT. Preclinical studies revealed that tirzepatide alters gut microbiota composition, specifically increasing Bacteroidetes and decreasing Firmicutes, while also enhancing intestinal barrier integrity.

Clinical trials have consistently shown tirzepatide provides improved glycemic control and weight loss compared to current treatments, alongside benefits such as improved lipid profiles and reduced hepatic steatosis. Further findings suggest potential protective effects for the heart and kidneys, highlighting its broad therapeutic scope beyond its primary indications.